SBS seeks lead plaintiff in Capricor securities class action over Deramiocel claims
Schall, Brown & Schwartz LLP says it is seeking a lead plaintiff in a securities class action against Capricor Therapeutics over alleged misleading statements tied to Deramiocel and its FDA application.
Schall, Brown & Schwartz LLP says it is pursuing a securities class action against Capricor Therapeutics Inc. and is inviting CAPR shareholders who bought during a listed class period to contact the firm about lead plaintiff status.
The lawsuit centers on allegations that Capricor made false and misleading statements about Deramiocel, the FDA and the company’s Biologics License Application. The claims have not been adjudicated.
In a PR Newswire release dated Aug. 27, 2026, the law firm said the suit alleges violations of Section 10(b), Section 20(a) and SEC Rule 10b-5 under the Securities Exchange Act of 1934. The class period listed in the release runs from Dec. 17, 2025, through July 26, 2026.
The release says the complaint alleges Capricor changed the statistical analysis plan for clinical data tied to Deramiocel without FDA agreement before resubmitting its biologics license application. It also says the company faced a significant risk that the FDA would not approve the application because of insufficient evidence of effectiveness.
Schall, Brown & Schwartz said investors suffered damages when the market learned the truth. The release also says shareholders who purchased CAPR shares during the class period may contact the firm about possible lead plaintiff appointments, but lead plaintiff status is not required to participate in any recovery.
The release identifies Schall, Brown & Schwartz as a national shareholder rights litigation firm. It also says the class has not yet been certified, and that a person who takes no action can remain an absent class member.
The firm provided contact details in the release for Brian Schall and David Schwartz, including its Los Angeles office address, phone number, website and email. The release also includes an attorney-advertising disclaimer.
The release does not say when the next court date will be.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.